Literature DB >> 10604491

Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients.

M A Tedesco1, G Ratti, S Mennella, G Manzo, M Grieco, A C Rainone, D Iarussi, A Iacono.   

Abstract

We examined long-term changes in cognitive function and quality of life (QL) in hypertensive patients by comparing the antihypertensive effect of hydrochlorothiazide (HCTZ) and losartan. We studied 69 patients (age range, 30 to 73 years) with mild-to-moderate hypertension. All patients, in a double-blind study, were randomly allocated to either treatment with 50 mg losartan once daily or 25 mg HCTZ once daily. The sample in each treatment group was divided by age (younger than 60 years or 60 years or older). At baseline and after 26 months, a QL questionnaire appropriate for the hypertensive patients was given. Cognitive function was evaluated, at baseline and after 26 months, by psychometric tests consisting of items from the Mini-Mental State Examination (MMSE) and the Sandoz Clinical Assessment Geriatric (SCAG). A score of less than 24 on the MMSE and more than 40 on the SCAG was predictive of cognitive impairment. The losartan group had a significant improvement in SCAG (P<.001) and MMSE (P<.001). No significant changes were observed in the HCTZ group (SCAG, P = .1; MMSE, P = .2). Sixty-five percent of the elderly had a MMSE score less than 24 and 70% had a SCAG score greater than 40, v. 35% and 48%, respectively, in younger patients. The health state index of QL improved significantly in both groups (losartan group, P<.01; HCTZ group, P<.02); the improvement in QL scores in patients using HCTZ was significant only in subjects aged 60 years and older (P<.04). These results suggest that losartan can have a positive effect not only on blood pressure but also on impaired cognitive function, reversing even minimal cognitive deficits induced by hypertension. The elderly patients in our sample had worse scores and cognitive performance was lower than in younger patients, even if in the losartan group the score improvement was the same at all ages. The same could not be said for HCTZ.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10604491     DOI: 10.1016/s0895-7061(99)00156-9

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  32 in total

Review 1.  Does the angiotensin II receptor antagonist losartan improve cognitive function?

Authors:  Michele A Tedesco; Gennaro Ratti; Giovanni Di Salvo; Francesco Natale
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

2.  Effects of treatment for hypertension on cognitive function in the elderly.

Authors:  Michael A Weber
Journal:  Curr Hypertens Rep       Date:  2006-08       Impact factor: 5.369

Review 3.  The relationship between blood pressure and cognitive function.

Authors:  Vera Novak; Ihab Hajjar
Journal:  Nat Rev Cardiol       Date:  2010-10-26       Impact factor: 32.419

Review 4.  Health-related quality-of-life measurement in hypertension. A review of randomised controlled drug trials.

Authors:  I Côté; J P Grégoire; J Moisan
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

Review 5.  [Alzheimer Disease].

Authors:  Fadi Massoud
Journal:  Can Fam Physician       Date:  2007-01       Impact factor: 3.275

Review 6.  Effect of antihypertensive agents on quality of life in the elderly.

Authors:  Roberto Fogari; Annalisa Zoppi
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

7.  Update on the pharmacological treatment of Alzheimer's disease.

Authors:  Fadi Massoud; Serge Gauthier
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

Review 8.  Cognitive-enhancing effects of angiotensin IV.

Authors:  Paul R Gard
Journal:  BMC Neurosci       Date:  2008-12-03       Impact factor: 3.288

9.  The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition.

Authors:  Ihab Hajjar; Meaghan Hart; William Milberg; Vera Novak; Lewis Lipsitz
Journal:  BMC Geriatr       Date:  2009-11-18       Impact factor: 3.921

10.  Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis.

Authors:  Nien-Chen Li; Austin Lee; Rachel A Whitmer; Miia Kivipelto; Elizabeth Lawler; Lewis E Kazis; Benjamin Wolozin
Journal:  BMJ       Date:  2010-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.